Valeant Pharma Settles SEC Accounting Probe For $45M
Bausch Health agreed to pay the U.S. Securities and Exchange Commission $45 million on Friday to settle allegations of accounting fraud dating back to when the company was known as Valeant...To view the full article, register now.
Already a subscriber? Click here to view full article